Ophthalmology Research: An International Journal

Background & Scope: Ocular drug delivery is inherently limited by anatomical and physiological barriers such as rapid tear turnover, blinking, nasolacrimal drainage, and restricted corneal permeability. These protective mechanisms substantially reduce drug residence time and bioavailability following topical administration, particularly with conventional eye drops, necessitating frequent dosing and compromising patient adherence. Sustained-release (SR) ophthalmic systems have emerged as a strategic approach to overcome these limitations by enabling prolonged drug retention and controlled therapeutic exposure.

Methodology: This review systematically evaluates recent advancements in SR ocular drug delivery technologies. Both formulation-driven and device-based platforms are examined, including in situ gelling systems, polymeric and lipid nanoparticles, liposomes / Niosomes, ocular inserts and films, implants, and microneedle-assisted delivery systems. Emerging technologies and innovations, including 3D printing, smart contact lenses, gene therapy and biologics, as well as bioadhesive and mucoadhesive systems, were discussed. Key aspects such as formulation design principles, drug release kinetics, translational considerations, and progression from preclinical studies to clinical application are critically analyzed.

Results & Discussion: Emerging SR platforms demonstrate improved precorneal retention, sustained therapeutic concentrations, and enhanced patient compliance compared with conventional formulations. Advances in material science and microfabrication have enabled precise control over drug release profiles and targeting efficiency. However, challenges persist, including sterility assurance, long-term safety, scalability, regulatory complexity, and manufacturing feasibility, which influence successful clinical translation.

Conclusion: Sustained-release ophthalmic delivery systems represent a transformative advancement in ocular therapeutics, offering the potential to address longstanding bioavailability constraints and unmet clinical needs. Continued integration of innovative materials, device engineering, and regulatory alignment will be essential to accelerate commercialization and optimize patient outcomes in ocular disease management.